UPDATE: Piper Jaffray Initiates Coverage on Amgen on Expected Attractive Returns
November 27, 2013 at 11:04 AM EST
In a report published Wednesday, Piper Jaffray analyst Joshua E. Schimmer initiated coverage on Amgen (NASDAQ: AMGN ) with an Overweight rating and $143.00 price target. In the report, Piper Jaffray noted, “We are initiating, resuming or assuming coverage on 16 biotechnology companies. We believe the outlook for the biotech